靶向二代测序在挪威儿童糖尿病登记处抗体阴性糖尿病病例中检出高达6.5%的MODY
在挪威儿童糖尿病登记处3882名儿童中,对469名GAD和IA-2双抗体阴性者及469名抗体阳性匹配对照行靶向二代测序筛查HNF1A、HNF4A、HNF1B、GCK和INS基因。抗体阴性组6.5%携带3-5类变异(对照2.4%,p=0.002),4-5类为4.1%(对照0.2%,p=1.6×10-5)。作者建议考虑对全部抗体阴性儿童行分子筛查。
要点
- 抗体阴性糖尿病患儿中6.5%检出3-5类MODY相关变异,显著高于抗体阳性对照的2.4%。
- 严格分类(4-5类)时抗体阴性组为4.1%,对照仅0.2%(p=1.6×10-5)。
- HNF1A的3-5类变异富集最强,抗体阴性组3.9% vs 对照0.4%(p=0.0002)。
核心结论
- 抗体阴性儿童糖尿病中MODY患病率可能高达6.5%,其中三分之一未被临床医生识别。
- 作者认为精确诊断对治疗和遗传咨询重要,建议将全部抗体阴性儿童的分子筛查纳入常规诊断。
研究设计与样本
- 在挪威儿童糖尿病登记处3882名儿童中,选取469名GAD和IA-2双抗体阴性者及469名抗体阳性匹配对照。
- 采用二代测序筛查HNF1A、HNF4A、HNF1B、GCK和INS基因,按临床诊断标准将变异分为1类(中性)至5类(致病)。
主要发现
- 病例与对照共识别58个罕见外显子和剪接变异。
- 抗体阴性患者中6.5%携带3-5类变异,对照为2.4%(p=0.002)。
- 严格分类(4和5类)时抗体阴性组为4.1%,对照为0.2%(p=1.6×10-5)。
- HNF1A的3-5类变异富集最强,抗体阴性组3.9% vs 对照0.4%(p=0.0002)。
- 抗体阴性者中携带3类变异者的表型与携带4和5类变异者相似。
关键数值与推荐
- 3-5类变异:抗体阴性组6.5% vs 对照2.4%(p=0.002)。
- 4-5类变异:抗体阴性组4.1% vs 对照0.2%(p=1.6×10-5)。
- HNF1A 3-5类变异:抗体阴性组3.9% vs 对照0.4%(p=0.0002)。
临床怎么用
- 作者建议(原文为should be considered)将全部抗体阴性儿童的分子筛查纳入常规诊断。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
AIMS/HYPOTHESIS: MODY can be wrongly diagnosed as type 1 diabetes in children. We aimed to find the prevalence of MODY in a nationwide population-based registry of childhood diabetes. METHODS: Using next-generation sequencing, we screened the HNF1A, HNF4A, HNF1B, GCK and INS genes in all 469 children (12.1%) negative for both GAD and IA-2 autoantibodies and 469 antibody-positive matched controls selected from the Norwegian Childhood Diabetes Registry (3882 children). Variants were classified using clinical diagnostic criteria for pathogenicity ranging from class 1 (neutral) to class 5 (pathogenic). RESULTS: We identified 58 rare exonic and splice variants in cases and controls. Among antibody-negative patients, 6.5% had genetic variants of classes 3-5 (vs 2.4% in controls; p = 0.002). For the stricter classification (classes 4 and 5), the corresponding number was 4.1% (vs 0.2% in controls; p = 1.6 × 10-5). HNF1A showed the strongest enrichment of class 3-5 variants, with 3.9% among antibody-negative patients (vs 0.4% in controls; p = 0.0002). Antibody-negative carriers of variants in class 3 had a similar phenotype to those carrying variants in classes 4 and 5. CONCLUSIONS/INTERPRETATION: This is the first study screening for MODY in all antibody-negative children in a nationwide population-based registry. Our results suggest that the prevalence of MODY in antibody-negative childhood diabetes may reach 6.5%. One-third of these MODY cases had not been recognised by clinicians. Since a precise diagnosis is important for treatment and genetic counselling, molecular screening of all antibody-negative children should be considered in routine diagnostics.
引用
- Johansson BB, Irgens HU, Molnes J, et al. Targeted next-generation sequencing reveals MODY in up to 6.5% of antibody-negative diabetes cases listed in the Norwegian Childhood Diabetes Registry. Diabetologia. 2016. PMID: 27913849. doi:10.1007/s00125-016-4167-1
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。